user

TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI

被引：26
|
作者：
Ahn, M. [1 ]
Han, J. [2 ]
Sequist, L. [3 ]
Cho, B. C. [4 ]
Lee, J. S. [5 ]
Kim, S. [6 ]
Su, W. [7 ]
Tsai, C. [8 ]
Yang, J. C. [9 ]
Yu, H. [10 ]
Horn, L. [11 ]
Lee, K. [12 ]
Haddad, V. [13 ]
Frigault, M. [14 ]
Ahmed, G. [13 ]
Yang, L. [15 ]
Ghiorghiu, D. [13 ]
Oxnard, G. [16 ]
机构：
[1] Samsung Med Ctr, Seoul, South Korea
[2] Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Yonsei Canc Ctr, Med Oncol, Seoul, South Korea
[5] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea
[6] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[7] Natl Cheng Kung Univ Hosp, Tainan, Taiwan
[8] Taipei Vet Gen Hosp, Dept Chest Med, Taipei, Taiwan
[9] Natl Taiwan Univ Hosp, Taipei, Taiwan
[10] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[11] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[12] Taipei Med Univ, Shuang Ho Hosp, Taipei, Taiwan
[13] Astrazeneca, Cambridge, England
[14] Astrazeneca, Waltham, MA USA
[15] Astrazeneca, Shanghai, Peoples R China
[16] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
non-small cell lung cancer; EGFR-Mutant; MET-amplification;
D O I：
10.1016/j.jtho.2017.09.377
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA 09.03
引用
收藏
页码：S1768 / S1768
页数：1
相关论文
共 50 条
  • [21] Osimertinib for EGFR-Mutant NSCLC Patients With Acquired T790M and EGFR Amplification After First-Generation EGFR-TKI Resistance
    Zhang, Yidan
    Xu, Yingqi
    Xu, Jianlin
    Zhong, Hua
    Xia, Jinjing
    Zhong, Runbo
    CANCER SCIENCE, 2024,
  • [22] Tepotinib Plus an EGFR TKI in Patients with EGFR-mutant NSCLC and Resistance to EGFR TKIs Due to MET Amplification (METamp)
    Liam, C. K.
    Ahmad, A. Rozila
    Hsia, T.
    Li, J. Y.
    Le, X.
    Heymach, J.
    Yang, J. C.
    Soo, R.
    Zhang, Y.
    Kim, S.
    Shin, S. W.
    Johne, A.
    Karachaliou, N.
    Bruns, R.
    Ellers-Lenz, B.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1118 - S1119
  • [23] SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET driven (MET plus ), locally advanced or metastatic non small cell lung cancer (NSCLC), following disease progression on osimertinib.
    Oxnard, Geoffrey R.
    Cantarini, Mireille
    Frewer, Paul
    Hawkins, George
    Peters, Jane
    Howarth, Paul
    Ahmed, Ghada F.
    Sahota, Tarjinder
    Hartmaier, Ryan
    Li-Sucholeiki, Xiaocheng
    Ahn, Myung-Ju
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] SANOVO: A Phase 3 Study of Savolitinib or Placebo in Combination with Osimertinib in Patients with EGFR-mutant and MET Overexpressed NSCLC
    Zhou, Q.
    Li, J.
    Wang, J.
    Yang, L.
    Fang, J.
    Dong, X.
    Yi, T.
    Min, X.
    Xu, F.
    Chen, J.
    Zhong, D.
    Bai, J.
    Liu, L.
    Zeng, A.
    Tang, J.
    Wu, H.
    Luo, X.
    Yu, J.
    Su, W.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S429 - S429
  • [25] Tepotinib plus gefitinib in patients with MET-amplified EGFR-mutant NSCLC: Long-term outcomes of the INSIGHT study
    Park, K.
    Zhou, J.
    Kim, D-W.
    Ahmad, A. R.
    Soo, R. A.
    Bruns, R.
    Straub, J.
    Johne, A.
    Scheele, J.
    Yang, J. C-H.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [26] The MET inhibitor ABN401 in combination with the thirdgeneration EGFR-TKI is effective MET-amplified and EGFRmutant NSCLC with acquired resistance to third-generation EGFR-TKI in preclinical models
    Yu, M. R.
    Yun, M. R.
    Lee, S.
    Rajasekaran, N.
    Park, K. E.
    Kim, N. Y.
    Hong, S.
    Oh, S. Y.
    Lee, Y. W.
    Lee, E. J.
    Kim, C. G.
    Lim, S. M.
    Choi, J.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1085 - S1086
  • [27] SCC244 plus osimertinib in patients with stage IIIB/IIIC or IV, EGFR TKI resistant EGFR-mutant NSCLC harboring MET amplification
    Yu, Y.
    Yang, N.
    Zhang, Y.
    Zhang, H.
    Li, M.
    Yu, Q.
    Zhou, J.
    Hu, X.
    Fang, J.
    Zhao, H.
    Feng, J.
    Li, L.
    Shu, Y.
    Wang, X.
    Sun, M.
    Zhang, J.
    Li, M.
    Ren, Y.
    Lu, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1553 - S1553
  • [28] Effect of smoking habits on the efficacy of EGFR-TKI plus anti-angiogenic agent in advanced EGFR-mutant NSCLC
    Qin, Bao-Dong
    Jiao, Xiao-Dong
    Wang, Yan
    Wu, Ying
    Ling, Yan
    Liu, Ke
    Zang, Yuan-Sheng
    LUNG CANCER, 2022, 170 : 91 - 97
  • [29] A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy
    Song, Jiangdian
    Shi, Jingyun
    Dong, Di
    Fang, Mengjie
    Zhong, Wenzhao
    Wang, Kun
    Wu, Ning
    Huang, Yanqi
    Liu, Zhenyu
    Cheng, Yue
    Gan, Yuncui
    Zhou, Yongzhao
    Zhou, Ping
    Chen, Bojiang
    Liang, Changhong
    Liu, Zaiyi
    Li, Weimin
    Tian, Jie
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 3583 - 3592
  • [30] Detailed characterization of combination treatment with MET inhibitor plus EGFR inhibitor in EGFR-mutant and MET-amplified non-small cell lung cancer
    Lee, Youngjoo
    Park, Seog-Yun
    Lee, Geon Kook
    Lim, Hyun-Ju
    Choi, Yu-Ra
    Kim, Jaemin
    Han, Ji-Youn
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (10)
12345